Can Denali Therapeutics Inc. cover its short-term obligations?

Its current ratio is 9.28 — current assets exceed current liabilities.

Where does Denali Therapeutics Inc.'s balance sheet data come from?

Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Denali Therapeutics Inc. DNLI Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$208.43M+18.1%	$176.54M+37.2%	$128.68M-41.4%	$219.54M-25.6%
Short-term investments	$662.55M+0.8%	$657.37M-27.6%	$907.41M-18.8%	$1.12B+95.5%
Restricted cash	$3.1M+93.8%	$1.6M—	——	——
Prepaid expenses and other current assets	$32.78M+2.1%	$32.11M+8.4%	$29.63M-17.9%	$36.1M+18.0%
Total current assets	$900.66M+4.2%	$864.44M-18.8%	$1.06B-22.5%	$1.37B+52.9%
Property and equipment, net	$52.4M-5.1%	$55.24M+21.2%	$45.59M+3.4%	$44.09M+13.4%
Operating lease right-of-use assets	$19M-16.9%	$22.86M-12.2%	$26.05M-14.4%	$30.44M-1.0%
Intangible assets, net	$0—	——	——	——
Other non-current assets	$25.94M+4.8%	$24.74M+36.4%	$18.14M+35.4%	$13.4M+12.9%
Allowance for credit losses	$0—	$0—	$0—	$0—
Total assets	$1.14B-16.7%	$1.37B+19.1%	$1.15B-21.0%	$1.46B+4.0%
Accounts payable	$505K-95.5%	$11.14M+17.4%	$9.48M+240%	$2.79M-41.6%
Accrued expenses	$32.18M-64.7%	$91.07M+33.0%	$68.5M+1,461%	$4.39M-91.7%
Current portion of long-term debt	$83K—	——	——	——
Operating lease liabilities, current	$9.46M+13.9%	$8.31M+14.4%	$7.26M-0.8%	$7.32M+34.2%
Finance Lease Liability, Current	$83K-97.8%	$3.73M—	$0—	——
Total current liabilities	$98.35M-3.8%	$102.21M+31.1%	$77.98M-78.6%	$363.92M-3.8%
Operating lease liabilities, non-current	$27.21M-25.8%	$36.67M-18.5%	$44.98M-15.2%	$53.03M-9.4%
Finance lease liabilities	$5.53M-1.5%	$5.62M—	$0—	——
Total liabilities	$131.09M-9.3%	$144.5M+17.5%	$122.96M-70.6%	$417.81M+376,307%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$1.89M+6.8%	$1.77M+3.3%	$1.71M+1.5%	$1.69M+8.9%
Additional paid-in capital	$3.06B+10.8%	$2.76B+28.9%	$2.14B+6.3%	$2.02B+25.5%
Retained earnings	-$2.05B-33.3%	-$1.54B-37.9%	-$1.12B-15.0%	-$970.99M-50.5%
Accumulated other comprehensive income (loss)	$682K-66.2%	$2.02M+214%	$643K+109%	-$6.89M-176%
Total stockholders' equity	$1.01B-17.6%	$1.23B+19.3%	$1.03B-1.1%	$1.04B+8.3%
Total liabilities and stockholders' equity	$1.14B-16.7%	$1.37B+19.1%	$1.15B-21.0%	$1.46B+4.0%
Available-for-Sale Debt Securities - Amortized Cost	$759.84M-25.1%	$1.01B+11.9%	$906.41M-19.4%	$1.12B+12.5%
Cash, Cash Equivalents, and Marketable Securities	$760.88M-25.2%	$1.02B+12.0%	$907.41M-18.8%	$1.12B+12.1%
Short- term Investments	$662.55M+0.8%	$657.37M-27.6%	$907.41M-18.8%	$1.12B+95.5%
Available-for-Sale Securities (Non-Current)	$98.32M-72.6%	$359.37M—	$0—	$0-100%
Deferred Tax Assets and Other Non-Current Assets	$25.94M+4.8%	$24.74M+36.4%	$18.14M+35.4%	$13.4M+12.9%
Investments - Amortized Cost Basis	$759.84M-25.1%	$1.01B+11.9%	$906.41M-19.4%	$1.12B+12.5%
Net Investment in Lease	$19M-16.9%	$22.86M-12.2%	$26.05M-14.4%	$30.44M-1.0%
Other intangible assets—net	$0—	——	——	——
Long- term Investments	$98.32M-72.6%	$359.37M—	$0—	$0-100%
Operating lease right-of-use assets	$19M-16.9%	$22.86M-12.2%	$26.05M-14.4%	$30.44M-1.0%
Other non-current assets	$25.94M+4.8%	$24.74M+36.4%	$18.14M+35.4%	$13.4M+12.9%
Operating Lease Right-of-Use Assets in Other Assets	$19M-16.9%	$22.86M-12.2%	$26.05M-14.4%	$30.44M-1.0%
Software and Technology Licenses, Net	$25.94M+4.8%	$24.74M+36.4%	$18.14M+35.4%	$13.4M+12.9%
Accrued Manufacturing Costs	$32.18M+30.1%	$24.73M+14.5%	$21.59M+26.4%	$17.09M-10.1%
Other Commercial Liabilities	$97.85M+7.4%	$91.07M+33.0%	$68.5M+2.7%	$66.69M—
Accrued Liabilities, Current	$97.85M+7.4%	$91.07M+33.0%	$68.5M+2.7%	$66.69M—
Compensation and benefits	$32.18M+30.1%	$24.73M+14.5%	$21.59M+26.4%	$17.09M-10.1%
Total debt	$42.37M-22.0%	$54.32M+4.0%	$52.24M-13.4%	$60.35M-5.7%
Common Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common Stock Shares Issued	156.2M+8.3%	144.2M+4.2%	138.4M+1.8%	136M+11.2%
Convertible Preferred Stock Authorized Shares	40M0.0%	40M0.0%	40M0.0%	40M0.0%
Convertible Preferred Stock Issued Shares	0—	0—	0—	0—
Convertible Preferred Stock Outstanding Shares	0—	0—	0—	0—
Number of Exercisable Options	——	——	——	——
Number of Vested and Expected to Vest Options	——	——	——	——
Preferred Stock Par Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Share-Based Payment Award Options Outstanding - Number	21.3M+14.3%	18.7M+13.2%	16.5M+12.4%	14.7M+7.2%
Unrealized Gains on Investments	$1.05M-59.4%	$2.6M+160%	$998K+940%	$96K+9,500%
Unrealized Losses on Investments (Before Tax)	$20K-91.0%	$223K+7,333%	$3K-100.0%	$6.64M+209%
Weighted Average Exercise Price of Exercisable Options	——	——	——	——
Weighted Average Exercise Price of Outstanding Options	$26.39+1.5%	$25.99-4.9%	$27.34+1.1%	$27.03+11.1%
Weighted Average Exercise Price of Vested and Expected to Vest Options	——	——	——	——
Cumulative Cost Basis	$759.84M-25.1%	$1.01B+11.9%	$906.41M-19.4%	$1.12B+12.5%
Accrued clinical and other research & development costs	$22.28M—	——	——	——
Accrued manufacturing costs	$5.34M—	——	——	——
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax	$20K-91.0%	$223K+7,333%	$3K-100.0%	$6.64M+209%
Gross Unrealized Gains	$1.05M-59.4%	$2.6M+160%	$998K+940%	$96K+9,500%
Total	$759.84M-25.1%	$1.01B+11.9%	$906.41M-19.4%	$1.12B+12.5%
Available for sale investments	$760.88M-25.2%	$1.02B+12.0%	$907.41M-18.8%	$1.12B+12.1%
Common stock, par value (in dollars per share)	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Common stock, shares authorized (in shares)	$400M0.0%	$400M0.0%	$400M0.0%	$400M0.0%
Common stock, shares issued (in shares)	$156.18M+8.3%	$144.22M+4.2%	$138.39M+1.8%	$135.97M+11.2%
Common Stock, Shares, Outstanding	$156.18M+8.3%	$144.22M+4.2%	$138.39M+1.8%	$135.97M+11.2%
Off-balance sheet concentrations of credit risk	$0—	$0—	$0—	——
Debt Securities, Available-for-Sale, Allowance for Credit Loss	$0—	$0—	$0—	$0—
Deferred research and development funding liability, current	$21.1M+49.3%	$14.13M—	$0—	——
Deferred research and development funding liability, current	$21.1M—	——	——	——
Current maturities of long-term debt	$83K-97.8%	$3.73M—	$0—	——
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	$48.53M+2.1%	$47.53M—	$0—	——
Other accrued liabilities	$7.4M—	——	——	——
Preferred Stock, Par or Stated Value Per Share	$0.010.0%	$0.010.0%	$0.010.0%	$0.010.0%
Preferred Stock, Shares Authorized	$40M0.0%	$40M0.0%	$40M0.0%	$40M0.0%
Preferred Stock, Shares Issued	$0—	$0—	$0—	$0—
Preferred Stock, Shares Outstanding	$0—	$0—	$0—	$0—
Purchase Obligation	$44.3M—	——	——	——
Liability related to the revenue participation right agreement	$0—	——	——	——
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	——	——	——	——
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number	$21.33M+14.3%	$18.66M+13.2%	$16.49M+12.4%	$14.67M+7.2%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	——	——	——	——
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$26.39+1.5%	$25.99-4.9%	$27.34+1.1%	$27.03+11.1%
Purchase Obligation	$44.3M—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Can Denali Therapeutics Inc. cover its short-term obligations?: Its current ratio is 9.28 — current assets exceed current liabilities.
Where does Denali Therapeutics Inc.'s balance sheet data come from?: Every line is extracted from Denali Therapeutics Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.